

Maria Carmen Mir

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3061456/publications.pdf>

Version: 2024-02-01

31
papers

1,343
citations

567281

15
h-index

434195

31
g-index

34
all docs

34
docs citations

34
times ranked

1901
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Systemic Therapy for High-risk Muscle-invasive Bladder Cancer After Radical Cystectomy: Current Options and Future Opportunities. <i>European Urology Oncology</i> , 2022, 5, 726-731.	5.4	16
2	Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer. <i>European Urology Oncology</i> , 2022, 5, 722-725.	5.4	6
3	Reliable Prediction of Post-Operative Complicationsâ€™ Rate Using the G8 Screening Tool: A Prospective Study on Elderly Patients Undergoing Surgery for Kidney Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 3785.	2.4	5
4	Nomogram Predicting Bladder Cancerâ€™specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium. <i>European Urology Focus</i> , 2021, 7, 1347-1354.	3.1	21
5	Upstaging to pT3a in Patients Undergoing Partial or Radical Nephrectomy for cT1 Renal Tumors: A Systematic Review and Meta-analysis of Outcomes and Predictive Factors. <i>European Urology Focus</i> , 2021, 7, 574-581.	3.1	30
6	Management of Metastatic Nonclear Renal Cell Carcinoma: What Are the Options and Challenges?. <i>European Urology Oncology</i> , 2021, 4, 843-850.	5.4	4
7	Collaborative Review: Factors Influencing Treatment Decisions for Patients with a Localized Solid Renal Mass. <i>European Urology</i> , 2021, 80, 575-588.	1.9	48
8	Development of a Novel Risk Score to Select the Optimal Candidate for Cytoreductive Nephrectomy Among Patients with Metastatic Renal Cell Carcinoma. Results from a Multi-institutional Registry (REMARCC). <i>European Urology Oncology</i> , 2021, 4, 256-263.	5.4	24
9	Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. <i>World Journal of Urology</i> , 2021, 39, 4345-4354.	2.2	4
10	Available active surveillance follow-up protocols for small renal mass: a systematic review. <i>World Journal of Urology</i> , 2021, 39, 2875-2882.	2.2	8
11	Reply to Laurence Klotzâ€™s Letter to the Editor re: Jeremy Yeun-Chun Teoh, Daniele Castellani, Claudia Mercader, et al. A Quantitative Analysis Investigating the Prevalence of â€™Manelsâ€™ in Major Urology Meetings. <i>Eur Urol</i> 2021;80:442â€™9. <i>Eur Urol</i> 2021;80:e100. <i>European Urology</i> , 2021, 81, e26-e26.	1.9	1
12	The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 3.e17-3.e27.	1.6	29
13	Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2020, 3, 523-529.	5.4	33
14	Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 639.e1-639.e9.	1.6	15
15	Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity scoreâ€™matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. <i>BJU International</i> , 2020, 126, 114-123.	2.5	42
16	Ex-vivo confocal fluorescence microscopy for rapid evaluation of renal core biopsy. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 109-113.	3.9	14
17	Active surveillance for small renal masses in elderly patients does not increase overall mortality rates compared to primary intervention: a propensity score weighted analysis. <i>Minerva Urology and Nephrology</i> , 2020, , .	2.5	9
18	Triggers for delayed intervention in patients with small renal masses undergoing active surveillance: a systematic review. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 389-407.	3.9	26

#	ARTICLE	IF	CITATIONS
19	Trimodal therapy in muscle invasive bladder cancer management. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 650-662.	3.9	8
20	Robotic versus laparoscopic radical nephrectomy: a large multi-institutional analysis (ROSULA). <i>Urology</i> , 2019, 107, 107-113.	2.2	36
21	Does the Unexpected Presence of Non-organ-confined Disease at Final Pathology Undermine Cancer Control in Patients with Clinical T1N0M0 Renal Cell Carcinoma Who Underwent Partial Nephrectomy?. <i>European Urology Focus</i> , 2018, 4, 972-977.	3.1	12
22	Role of Active Surveillance for Localized Small Renal Masses. <i>European Urology Oncology</i> , 2018, 1, 177-187.	5.4	85
23	Partial Nephrectomy Versus Radical Nephrectomy for Clinical T1b and T2 Renal Tumors: A Systematic Review and Meta-analysis of Comparative Studies. <i>European Urology</i> , 2017, 71, 606-617.	1.9	328
24	Nutrition for cystectomy with pelvic lymph nodes dissection: perioperative considerations. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2016, 68, 150-60.	3.9	0
25	Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 67, 241-249.	1.9	235
26	Decline in Renal Function after Partial Nephrectomy: Etiology and Prevention. <i>Journal of Urology</i> , 2015, 193, 1889-1898.	0.4	240
27	Analysis of Atrophy After Clamped Partial Nephrectomy and Potential Impact of Ischemia. <i>Urology</i> , 2015, 85, 1417-1423.	1.0	16
28	Editorial Comment to Performance comparisons in major urological oncological surgeries between the USA and Japan. <i>International Journal of Urology</i> , 2014, 21, 1150-1150.	1.0	0
29	Predicting Risk of Bladder Cancer Using Clinical and Demographic Information from Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Participants. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2241-2249.	2.5	7
30	Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome. <i>BJU International</i> , 2011, 108, E71-6.	2.5	31
31	Is there a relationship between prostate volume and Gleason score?. <i>BJU International</i> , 2008, 102, 563-565.	2.5	8